Full-Time

Animal Care Technician II

Posted on 1/15/2025

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Compensation Overview

$99k - $109k/yr

Junior, Mid

San Bruno, CA, USA

Category
Veterinary Professionals
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • 2+ years of related experience.
  • Must have experience handling and routine health evaluation of rodents
  • Must be familiar with and able to apply industry standards, animal welfare regulations including the Guide for the Care and Use of Laboratory Animals
  • Must have basic computer skills (Word, Excel)
  • Candidates must be able to work independently, and in a team, and maintain a high level of attention to detail
  • Candidate must have good spoken and written communication skills
  • Ability to manage time and resources effectively
  • Ability and willingness to work weekends and/or holidays
Responsibilities
  • Perform and document routine husbandry care
  • Daily health and environmental checks – report any health or environmental problems to Vivarium manager and Principal Investigators
  • Rodent cage change/sanitation
  • Organize and maintain cage staging areas for optimal efficiency
  • Perform daily and routine maintenance, restocking of and sanitation of vivarium areas
  • Receive animal shipments, assess animal health, and house animals appropriately
  • Manage stocks of and coordinate purchase and receipt of animal food/bedding/consumables/caging materials as needed
  • Maintain compliance with IACUC guidelines and the Guide for the Care and Use of Laboratory Animals and other relevant regulatory requirements as appropriate
  • Interact with Facilities, vendors and service/repair contractors to address any mechanical or facility issues
Desired Qualifications
  • An A.S. degree, AALAS certification, or equivalent qualification is highly preferred
  • Experience with operation of industrial cage wash equipment and autoclave
  • Experience with Hydropac water pouch system a plus
  • Experience in basic in vivo techniques a strong plus (body weights/condition scoring, post-surgical evaluations, animal restraint and or dosing techniques)

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, targeting conditions like heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Size

501-1,000

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on personalized medicine aligns with Cytokinetics' tailored treatment approach.
  • AI in drug discovery could enhance Cytokinetics' R&D efficiency and reduce time to market.
  • FDA initiatives expedite approval for rare disease drugs, benefiting Cytokinetics' pipeline.

What critics are saying

  • Increased competition from Imbria Pharmaceuticals may impact Cytokinetics' market share.
  • Sanofi's rights to Aficamten in Greater China may limit Cytokinetics' market access.
  • Public offering at $51/share may dilute existing shareholder value and affect stock performance.

What makes Cytokinetics unique

  • Cytokinetics focuses on first-in-class muscle activators and next-in-class muscle inhibitors.
  • The company targets cardiovascular and neuromuscular diseases with unmet medical needs.
  • Cytokinetics has a robust pipeline including omecamtiv mecarbil and reldesemtiv.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
GlobeNewswire
Apr 10th, 2025
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO

– Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA...

Here Novi
Mar 21st, 2025
Cytokinetics Launches EARTH-HCM for Hypertrophic Cardiomyopathy Awareness

Cytokinetics launches EARTH-HCM for hypertrophic cardiomyopathy awareness.

Investing.com
Mar 20th, 2025
Cytokinetics launches interactive HCM public health tool

Cytokinetics launches interactive HCM public health tool.

Medical Update Online
Mar 19th, 2025
Cytokinetics to present new findings on Aficamten and hypertrophic cardiomyopathy at ACC 2025

Cytokinetics to present new findings on Aficamten and hypertrophic cardiomyopathy at ACC 2025.

Stock Titan
Jan 6th, 2025
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.

INACTIVE